Abbott Laboratories (ABT) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $88.46, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international sales (61.0%); Weak growth.
Abbott Laboratories develops, manufactures, and sells healthcare products across four segments: Established Pharmaceuticals (branded generics sold in emerging markets), Diagnostic Products, Nutritional Products, and Medical Devices including FreeStyle Libre CGM and MitraClip.... Read more
Hold if already holding. Not a fresh buy at $88.46, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international sales (61.0%); Weak growth. Chart setup: Death cross but MACD improving, RSI 56. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.1/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 30d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated 2026-06-15Recent Developments — Abbott Laboratories
Latest news
- NEWS Abbott Laboratories Boosts Dividend, Stock Recovers from Mid-Year Pullback (NYSE:ABT) - Stock Investor — Stock Investor positive
- NEWS Abbott Laboratories (ABT) Set for Q1 Earnings Report with Modest Growth Expectations - GuruFocus — GuruFocus neutral
- NEWS Abbott Laboratories Insiders Added US$3.10m Of Stock To Their Holdings - Yahoo Finance — Yahoo Finance positive
- NEWS Is Abbott (ABT) the Best Oversold Blue Chip Stock to Buy? - Yahoo Finance — Yahoo Finance positive
- NEWS Abbott (ABT) stock rated buy on strong diabetes trial results - MSN — MSN positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicinternational sales61%10-K Item 1A: 'Sales outside of the U.S. in 2025 made up approximately 61 percent of Abbott's net sales'
Material Events(8-K, last 90d)
- 2026-04-27Item 5.02LOWKevin Conroy named to Abbott Board of Directors on April 24, 2026. Shareholders also approved 2026 Incentive Stock Program at Annual Meeting, replacing the 2017 Program. Routine board appointment; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $88.46, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international sales (61.0%); Weak growth. Chart setup: Death cross but MACD improving, RSI 56. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $104.89 (+18.6%), stop $84.39 (−4.8%), A.R:R 3.7:1. Score 5.1/10, moderate confidence.
Take-profit target: $104.89 (+18.6% upside). Target $104.89 (+18.6%), stop $84.39 (−4.8%), A.R:R 3.7:1. Stop-loss: $84.39.
Concentration risk — Geographic: international sales (61.0%); Weak growth; Negative momentum.
Abbott Laboratories trades at a P/E of 24.7 (forward 14.6). TrendMatrix value score: 6.4/10. Verdict: Hold.
34 analysts cover ABT with a consensus score of 4.0/5. Average price target: $117.
What does Abbott Laboratories do?Abbott Laboratories develops, manufactures, and sells healthcare products across four segments: Established...
Abbott Laboratories develops, manufactures, and sells healthcare products across four segments: Established Pharmaceuticals (branded generics sold in emerging markets), Diagnostic Products, Nutritional Products, and Medical Devices including FreeStyle Libre CGM and MitraClip. Approximately 61% of net sales came from outside the United States in 2025, with roughly 115,000 employees serving customers in more than 160 countries.